CAMBRIDGE, Mass., November 6, 2025 – The INTREPID Alliance, a not-for-profit consortium of innovative biopharmaceutical companies and associations committed to accelerating antiviral research, today announced that it will present data from its latest Antiviral Clinical and Preclinical Development Landscape at the American Society of Tropical Medicine and Hygiene (ASTMH) 2025 Annual Meeting, taking place November 9-13, 2025, in Toronto, Canada.

Jim Demarest, Ph.D., Scientific Consultant, INTREPID Alliance and John C. Pottage, Jr., M.D., Lead Scientific Consultant, INTREPID Alliance will present findings that map current antiviral development activity for vector- and contact-transmitted viruses. The analysis reveals significant unmet needs across preclinical and clinical pipelines and will be shared in a poster titled, “Significant Gaps in the Antiviral Landscape for Vector/Contact-Transmitted Viral Infections of Pandemic Potential: A Call-to-Action.”

The poster (LB-9257) will be presented during Session B on Tuesday, November 11, from 12:00-1:45pm in the Poster Hall E.

View the poster here.

# # #

Disclaimer

The INTREPID Alliance is a not-for-profit consortium of innovative biopharmaceutical companies and associations committed to accelerating antiviral research, aiming to ensure that we have a stronger pipeline and are better prepared to respond to future pandemic and endemic threats.

As part of our efforts, the INTREPID Alliance publishes and maintains the Antiviral Toolbox to be a non-promotional resource with the purpose of knowledge-sharing and to support better pandemic preparedness. The Antiviral Toolbox includes the Registry of Antiviral Compound Libraries, a registry of compound libraries designed to facilitate research. These registries are third-party resources and have been developed independently of, and at arm’s length, from INTREPID Alliance and its members. The INTREPID Alliance is not responsible for their content. The INTREPID Alliance also publishes and maintains a centralized list of promising investigational compounds. These compounds have been selected based on objective, scientific criteria, using publicly available sources, and at arm’s length from commercial influence of our member companies. See criteria listed in the report “Antiviral Clinical Development Landscape and Promising Clinical Compounds.” The designation of certain compounds as promising is based upon currently available information, and exclusively upon an assessment against these criteria. “Promising” is not a promotional claim. Candidate compounds have not been assessed by regulatory authorities to be safe and efficacious for the treatment of disease in humans. Our content is designed to be factual, informative, and non-commercial. It is not designed or intended to advertise or promote any pharmaceutical product or therapy or to advance the commercial interests of any company.

ABOUT THE INTREPID ALLIANCE

The INTREPID Alliance aims to accelerate the development of new treatments for emerging viral pandemic agents through facilitating early science and R&D, policy and advocacy, and stakeholder engagement. Led by a not-for-profit consortium of innovative biopharmaceutical companies and associations and working with the public, private and not-for-profit sectors, INTREPID works to bridge key gaps and unmet needs to ensure delivery of antiviral solutions to viral pathogens with the greatest pandemic potential.

INTREPID was launched in March 2023 at a high-level summit bringing together more than 100 thought leaders in virology and global health. For a read-out from the summit and additional information, visit www.intrepidalliance.org.

CONTACT

Nina M. Hill, Ph.D., Head of Secretariat, INTREPID Alliance, [email protected]